Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manni, A.
Right arrow Articles by Badger, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manni, A.
Right arrow Articles by Badger, B.

Clinical Cancer Research, Vol 2, Issue 11 1901-1906, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer

A Manni, D Mauger, P Gimotty and B Badger
Department of Medicine and Center for Biostatistics and Epidemiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.

Although considerable experimental evidence suggests an important role of polyamines in breast cancer biology, compelling supportive data in patients are lacking. To address this issue, we measured ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase, and spermidine/spermine acetyltransferase (the three key polyamine metabolic enzymes) in a cohort of 50 primary human breast cancers and related their levels of activity to disease-free survival and overall survival. The major finding of our study was that ODC activity level was a negative independent prognostic factor for both end points. With regard to overall survival, the adverse influence of ODC expression was superior even to that provided by the number of positive nodes. Furthermore, the statistical significance of the ODC effect on survival was enhanced when breast cancer-specific mortality was included in the analysis as opposed to death from any cause. In addition, high tumor ODC activity may predict a shorter time from recurrence to death, although this effect was of only borderline statistical significance. In summary, these results provide the first concrete evidence supporting the prognostic role of ODC in human breast cancer.


This article has been cited by other articles:


Home page
Cancer Res.Home page
X. Hu, S. Washington, M. F. Verderame, and A. Manni
Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells
Cancer Res., December 1, 2005; 65(23): 11026 - 11033.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
V. A. Levin, J. L. Jochec, L. M. Shantz, P. E. Koch, and A. E. Pegg
Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to Difluoromethylornithine
J. Histochem. Cytochem., November 1, 2004; 52(11): 1467 - 1474.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. K. Carducci, C. D. Riley, J. F. Bender, R. A. Casero Jr., and N. E. Davidson
A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5922 - 5928.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. A. Levin, K. R. Hess, A. Choucair, P. J. Flynn, K. A. Jaeckle, A. P. Kyritsis, W. K. A. Yung, M. D. Prados, J. M. Bruner, S. Ictech, et al.
Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination {alpha}-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas
Clin. Cancer Res., March 1, 2003; 9(3): 981 - 990.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al.
A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers
Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. Sun, A. Wollin, and A. M. Stephen
Moderate Folate Deficiency Influences Polyamine Synthesis in Rats
J. Nutr., September 1, 2002; 132(9): 2632 - 2637.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. A. O'Shaughnessy, L. M. Demers, S. E. Jones, J. Arseneau, P. Khandelwal, T. George, R. Gersh, D. Mauger, and A. Manni
{{alpha}}-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients
Clin. Cancer Res., November 1, 1999; 5(11): 3438 - 3444.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Canizares, J. Salinas, M. d. las Heras, J. Diaz, I. Tovar, P. Martinez, and R. Penafiel
Prognostic Value of Ornithine Decarboxylase and Polyamines in Human Breast Cancer: Correlation with Clinicopathologic Parameters
Clin. Cancer Res., August 1, 1999; 5(8): 2035 - 2041.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.